"If you're on Wall Street and you still think Pfizer and Moderna are good buys, I’ve got news for you: There’s some catalysts coming that are probably not going to be good for holding those stocks," he said.
Dowd said he also had examined the Pfizer clinical trial data provided by whistleblower...